Current development of CBP/p300 inhibitors in the last decade

He, ZX; Wei, BF; Zhang, X; Gong, YP; Ma, LY; Zhao, W

Ma, LY; Zhao, W (corresponding author), Zhengzhou Univ, Sch Pharmaceut Sci, State Key Lab Esophageal Canc Prevent & Treatment, Key Lab Adv Drug Preparat Technol,Minist Educ, Zhengzhou 450001, Peoples R China.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021; 209 ():

Abstract

CBP/p300, functioning as histone acetyltransferases and transcriptional co-factors, represents an attractive target for various diseases, including ma......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索